This is a pilot study to see whether a combination of two investigational drugs that target
the immune system can be given to people with colorectal cancer before surgically removing
the tumor. This study is also being done to see what side effects this combination of drugs
has and what effect they have on colorectal cancer. The two monoclonal antibodies are
balstilimab, a programmed cell death protein 1 (PD-1) inhibitor, and botensilimab, a
cytotoxic T lymphocyte-associated protein 4 (CTLA-4) inhibitor. Participants will receive a
dose of balstilimab and botensilimab, both given intravenously (IV), followed by a second
dose of balstilimab approximately 2 weeks after the first dose. Both doses of balstilimab and
the single dose of botensilimab will be given during an 8 weeks period before surgery.